Journal Article

DKFZ-2017-00900

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

Leichsenring, J. ; Volckmar, A.-L. ; Magios, N. ; Morais de Oliveira, C. M.DKFZ* ; Penzel, R. ; Brandt, R. ; Kirchner, M.DKFZ* ; Bozorgmehr, F. ; Thomas, M.DKFZ* ; Schirmacher, P.DKFZ* ; Warth, A. ; Endris, V. ; Stenzinger, A. (Last author)DKFZ*

2017
Wiley-Liss New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/gcc.22427

Abstract: Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9%) carried EGFR mutations targetable by TKIs (30.4% male patients, median age 65.1 y, 19.6% smokers with 12.8 median pack years). Seventy-nine patients (77.5%) received TKI therapy either as a first- or second-line therapy. Of the 102 EGFR-mutant tumors, 72 (70.6%) exhibited the p.Q787Q polymorphism and another 12 (11.8%) cases with p.Q787Q harbored an additional TKI insensitive mutation (p.T790M). The polymorphism was neither associated with classic clinicopathological parameters nor with overall survival (21.1 months vs. 20.1 months; P-value = 0.91) or clinical response (P-value = 0.122). The patients with p.T790M had worse survival compared to EGFR activating mutation carriers with and without p.Q787Q when analyzed as a separate group (27.5 months, P-value = 0.02). In conclusion, p.Q787Q is neither a suitable prognostic nor predictive biomarker for ADC patients receiving anti-EGFR therapy in first- or second-line of therapy. © 2016 Wiley Periodicals, Inc.

---

Contributing Institute(s):

1. DKTK Heidelberg (L101)
2. Tumor- und Serumbank (G035)
3. MT NCT Mol. Pathology Core (G825)
4. AD Palliative Oncology (G835)

Research Program(s):

1. 319H - Addenda (POF3-319H) (POF3-319H)

Appears in the scientific report 2017

---

Database coverage:
; BIOSIS Previews ; Current Contents - Life Sciences ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---